Editorial: Ex-vivo and in-vivo genome engineering for metabolic and neurometabolic diseases

Overview of attention for article published in Frontiers in Genome Editing, July 2023

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,885 followers.

Discover the research on Ex-vivo and In-vivo Genome Editing for Metabolic and Neurometabolic diseases in our latest Editorial in @FrontGenEditing

New Research: Editorial: Ex-vivo and in-vivo genome engineering for metabolic and neurometabolic diseases #GenomeEditing #CRISPR https://t.co/Slulv9dJuF

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.